Hyperoncotic albumin is not effective in the treatment of peripheral oedema

2020 ◽  
Vol 64 (7) ◽  
pp. 1025-1025 ◽  
Author(s):  
Ellis Muggleton
Keyword(s):  
Peripheral Oedema

A case of marked ascites and peripheral oedema

1987 ◽  
Vol 147 (2) ◽  
pp. 72-78
Author(s):  
Susan Faires ◽  
Mervyn Thomas ◽  
Robert Giles ◽  
Dennis Wakefield ◽  
James Yong ◽  
...  
Keyword(s):  
Peripheral Oedema

Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

2005 ◽  
Vol 2 (2) ◽  
pp. 61-66 ◽  
Author(s):  
Chetan Patel ◽  
Kathleen L Wyne ◽  
Darren K McGuire
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Peripheral Oedema

Alcohol not a predictor of peripheral oedema in chronic bronchitis: Authors' reply

BMJ ◽  
1993 ◽  
Vol 306 (6888) ◽  
pp. 1340-1340
Author(s):  
W. MacNee ◽  
N. J Douglas
Keyword(s):  
Chronic Bronchitis ◽  
Peripheral Oedema

Chronic peripheral oedema and lymphoedema

2010 ◽  
pp. 3083-3092
Author(s):  
Peter S. Mortimer
Keyword(s):  
Peripheral Oedema

In response: Hyperoncotic albumin is not effective in the treatment of peripheral oedema

2020 ◽  
Vol 64 (7) ◽  
pp. 1026-1027
Author(s):  
Robert G. Hahn ◽  
Randal O. Dull
Keyword(s):  
Peripheral Oedema

scholarly journals Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials

BMJ Open ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. e023600 ◽  
Author(s):  
Igho J Onakpoya ◽  
Elizabeth T Thomas ◽  
Joseph J Lee ◽  
Ben Goldacre ◽  
Carl J Heneghan
Keyword(s):  
Neuropathic Pain ◽  
Adverse Events ◽  
Meta Analysis ◽  
Peripheral Oedema ◽  
Phase Iii ◽  
Rapid Review ◽  
Secondary Outcome ◽  
Cord Injury ◽  
Quality Evidence

ObjectiveTo assess the benefits and harms of pregabalin in the management of neuropathic pain.DesignRapid review and meta-analysis of phase III, randomised, placebo-controlled trials.ParticipantsAdults aged 18 years and above with neuropathic pain defined according to the International Association for the Study of Pain criteria.InterventionsPregabalin or placebo.Primary and secondary outcome measuresOur primary outcomes were pain (as measured using validated scales) and adverse events. Our secondary outcomes were sleep disturbance, quality of life, Patient Global Impression of Change, Clinician Global Impression scale, anxiety and depression scores, overall discontinuations and discontinuations because of adverse events.ResultsWe included 28 trials comprising 6087 participants. The neuropathic pain conditions studied were diabetic peripheral neuropathy, postherpetic neuralgia, herpes zoster, sciatica (radicular pain), poststroke pain and spinal cord injury-related pain. Patients who took pregabalin reported significant reductions in pain (numerical rating scale (NRS)) compared with placebo (standardised mean difference (SMD) −0.49 (95% CI −0.66 to −0.32, p<0.00001), very low quality evidence). Pregabalin significantly reduced sleep interference scores (NRS) compared with placebo (SMD −0.38 (95% CI −0.50 to −0.26, p<0.00001), moderate quality evidence. Pregabalin significantly increased the risk of adverse events compared with placebo (RR 1.33 (95% CI 1.23 to 1.44, p<0.00001, low quality evidence)). The risks of experiencing weight gain, somnolence, dizziness, peripheral oedema, fatigue, visual disturbances, ataxia, non-peripheral oedema, vertigo and euphoria were significantly increased with pregabalin. Pregabalin was significantly more likely than placebo to lead to discontinuation of the drug because of adverse events (RR 1.91 (95% CI 1.54 to 2.37, p<0.00001), low quality evidence).ConclusionPregabalin has beneficial effects on some symptoms of neuropathic pain. However, its use significantly increases the risk of a number of adverse events and discontinuation due to adverse events. The quality of the evidence from journal publications is low.

Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription–Event Monitoring Study in England

Drug Safety ◽  
2016 ◽  
Vol 39 (11) ◽  
pp. 1093-1104 ◽  
Author(s):  
Deborah Layton ◽  
Abigail L. Coughtrie ◽  
Naseer Qayum ◽  
Saad A. W. Shakir
Keyword(s):  
Risk Factors ◽  
Peripheral Oedema ◽  
Prescription Event Monitoring ◽  
Event Monitoring ◽  
Monitoring Study

Peripheral Oedema in a Patient taking Olanzapine (A Case Report)

2011 ◽  
Vol 9 (2) ◽  
Author(s):  
MU Dada ◽  
A Obadeji ◽  
AO Ajayi
Keyword(s):  
Case Report ◽  
Peripheral Oedema

Peripheral oedema in quetiapine therapy

2012 ◽  
Vol 46 (8) ◽  
pp. 790-791 ◽  
Author(s):  
Alexia J McSkimming ◽  
Pallavi Dham ◽  
Jacob Alexander ◽  
Anthony Dinesh
Keyword(s):  
Peripheral Oedema
Sign in / Sign up

Export Citation Format

Share Document